Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
LONDON and CARLSBAD, Calif., Oct. 01, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering,...
-
LONDON and CARLSBAD, Calif., Sept. 27, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering,...
-
VIENNA, Austria, Aug. 28, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the development and commercialization of cannabinoid...
-
- Epidiolex® (cannabidiol) oral solution approved by FDA and on track to be launched in Fall -- Conference call today at 4:30 p.m. ET - LONDON and CARLSBAD, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE)...
-
LONDON, July 23, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel...
-
LONDON and CARLSBAD, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering,...
-
LONDON and CARLSBAD, Calif., June 06, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and...
-
– First dose-ranging study comparing pharmaceutical formulation of cannabidiol to placebo as add-on therapy in Lennox-Gastaut syndrome, a rare, severe and difficult to treat form of childhood-onset...
-
– First dose-ranging study comparing pharmaceutical formulation of cannabidiol to placebo as add-on therapy in Lennox-Gastaut syndrome, a rare, severe and difficult to treat form of childhood-onset...
-
GW Pharmaceuticals plc Reports Fiscal Second Quarter 2018 Financial Results and Operational Progress
- Positive unanimous vote at Epidiolex® (cannabidiol) FDA Advisory Committee meeting -- NDA PDUFA goal date scheduled for June 27, 2018 -- Conference call today at 4:30 p.m. EST - LONDON and...